Indoco Remedies: Compliance Certificate Under SEBI Regulations for Q4FY26
Indoco Remedies Limited received a compliance certificate for Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026, and confirms the proper processing and listing of dematerialised securities by the Registrar and Transfer Agent, MUFG Intime India Private Limited.
This is a standard regulatory filing confirming compliance with SEBI regulations for the quarter. It does not introduce any new material information that would significantly impact the company's operations or stock performance.
The announcement is a routine compliance filing and does not contain any new financial information or strategic developments that would impact the company's sentiment.
Indoco Remedies Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate, issued by MUFG Intime India Private Limited, the company's Registrar and Transfer Agent, confirms compliance for the quarter ended March 31, 2026.
The certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, states that securities received from depository participants for dematerialisation during the quarter were processed and confirmed with the depositories. It also confirms that the securities are listed on the stock exchanges where the company's existing securities are listed.
Furthermore, the registrar and transfer agent confirmed that security certificates received for dematerialisation were either confirmed or rejected. Mutilated and cancelled certificates were handled after due verification by the depository participant, and the names of the depositories were substituted in the company's register of members as the registered owner within the prescribed timelines.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.